-
CELLphenomics and Charles River Announce Agreement, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charles River clients with access to CELLphenomics’ proprietary 3D tumor model platform, PD3D®, which will expand Charles River’s 3D in vitro testing services to further optimize oncological approaches for its clients. CELLphenomics’ core competence is the establishment and cultivation of complex patient-derived 3D cell culture models (PD3D®) from various solid tumor tissues. These highly reliable and predictive preclinical PD3D models robustly recapitulate the biological properties of the donor tissue, including key histopathological features and genomic makeup. They are a powerful tool for disease modeling, biomarker, and drug discovery. CELLphenomics’ continuously growing biobank comprises more than 500…
-
KYAN Technologies, Alentis Therapeutics, and CELLphenomics Join Forces Combining Cutting-edge Optim.AI™ and PD3D® Models to Advance Claudin-1 Expression Research
KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and organ fibrosis. This partnership aims to accelerate research into Claudin-1 expression using innovative patientderived 3D (PD3D®) cell culture models provided by CELLphenomics. Claudin-1 (CLDN1) is a member of the tight junction protein family. In many solid tumours and during organ fibrosis CLDN1 is overexpressed and exposed outside of tight junctions, where it plays a key role in disease pathogenesis. Alentis is rapidly advancing a clinical pipeline of antibodies specifically targeting exposed CLDN1, unlocking a new mode of action to…
-
Berlin scientists use tumor samples drawn from patients with soft tissue sarcomas to individually test their tumor response to ionizing radiation and lay one stepstone towards a translational platform for personalized radiation oncology for rare malignant
Soft tissue sarcomas are a rare group of malignant tumors arising from connective tissue cells, of which more than 70 different subtypes are known to date. The standard therapy for localized, high-grade soft tissue sarcomas is surgery and pre- or postoperative radiation. Despite the known multitude of subtypes, according to US-American and European guidelines all subtypes of soft tissue sarcomas are treated with the identical radiation therapy plan in terms of dose as well as radiation field in the sense of a "one-sizefitsall" therapy. In a joint pilot study radio-oncologists Dr Siyer Roohani, PD Dr David Kaul from the Department of Radiation Oncology at Charité – Universitätsmedizin Berlin, oncologist Manuela…
-
Bowel cancer: Researchers find possible cause for chemoresistance and partially used patient-derived 3D cell culture models for their studies.
Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, but they also make it resistant to common forms of chemotherapy. This discovery was made by a research team led by Martin Luther University Halle-Wittenberg (MLU) and Saarland University with the collaboration of CELLphenomics. For its new study, published in the scientific journal “Molecular Cancer”, the team analysed more than 140 tissue samples from bowel cancer patients from the IMI project OncoTrack, from which CELLphenomics emerged as a spin-off. The researchers found a link between the concentration of IGF2BP2 and the characteristics of the tumours. The findings could help to develop better diagnostic procedures and possibly novel…
-
CELLphenomics’ and KYAN Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry
CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry. The combination of these two unique technologies will allow reliable conclusions about the treatability of the tumor and its functional causes of therapeutic success and/or failure, leading to novel treatment combinations and faster preclinical development of new anti-cancer drugs. KYAN’s technology platform, Optim.AI™, combined with CELLphenomics’ expertise in PD3D® model establishment and cultivation of patient-derived complex cell culture model cultures from…
-
European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types
Indivumed GmbH (“Indivumed”) and CELLphenomics GmbH (“CELLphenomics”) today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation. “Leveraging our multi-omics database and AI-driven oncology analytics is what allows us to decipher the complex mechanisms of cancer in order to drive the development of precision oncology,” said Prof. Dr. Hartmut Juhl, CEO and Founder…
-
Von der Europäischen Union finanziertes Projekt soll zu neuen Therapieansätzen verschiedener solider Tumorarten führen
Indivumed GmbH („Indivumed“) und CELLphenomics GmbH („CELLphenomics“) geben heute ihre Partnerschaft bekannt, in der eine bisher einzigartige Plattform entsteht, die eine schnellere und effizientere Identifizierung und Validierung therapeutischer Targets ermöglichen wird. Die neue Plattform kombiniert die KI-gestützten onkologischen Analysemethoden von Indivumed mit der Expertise von CELLphenomics im Bereich der Entwicklung von Organoid-Modellen, um therapeutisch relevante Targets identifizieren und diese Targets in vitro validieren zu können. In-silico-TargetDiscovery und -Development werden im Rahmen dieser Partnerschaft mit passenden Tumormodellen verknüpft und anschließend validiert, was die Entwicklung von Krebstherapeutika beschleunigen wird. „Mithilfe unserer Multi-omics-Datenbank und KI-gestützter Analysemethoden sind wir in der Lage, die komplexen Mechanismen von Tumoren zu entschlüsseln und so die Entwicklung der…
